HPS2-THRIVE: Game (Mostly) Over for Niacin (CME/CE)
(MedPage Today) -- Publication of landmark trial results affirmed no benefit and worrisome adverse events from adding extended-release niacin to statin therapy, but many physicians weren't ready to concede failure of the purported HDL mechanism.
CONCLUSION: Women with STEMI are less likely to receive invasive management, revascularisation, or preventive medication at discharge. The reasons for these persistent differences in care require investigation. PMID: 30025513 [PubMed - as supplied by publisher]
Over the decades, statin therapy, which reduces serum levels of low-density lipoprotein cholesterol (LDL-c), has been proved to reduce cardiovascular events by stabilizing atherosclerotic plaques; however, the risks are still residual [1 –3]. In such situation, we should consider not only LDL-c, but also other lipid profiles, including triglyceride, remnant-like particle cholesterol (RLP-c), and high-density lipoprotein cholesterol (HDL-c).
This study aimed to assess rate of LDL-cholesterol target attainment among patients with diabetes at very-high cardiovascular risk treated with statins, and to identify predictive factors of non-attainment of target in this population.
Authors: Harari E, Eisen A PMID: 30023119 [PubMed]
I met ophthalmologist and corneal specialist Dr. Peter Polack while speaking in Ocala, Florida. He told me that, by having his patients with dry eye—which has increased dramatically over the last 20 years—remove all wheat and grains, he is seeing this condition reverse within weeks, along with all the other health benefits. Unlike other ophthalmologists, who virtually have nothing to do with diet and therefore prescribe the costly drugs Restasis and Xiidra (each cost $500-$550 per month), Dr. Polack rarely has to resort to use of these awful agents. Here Dr. Polack speaks about his phenomenal experience. More a...
Controlling lipids, in particular cholesterol and low-density lipoprotein cholesterol, has been identified as a key intervention to prevent adverse systemic events in patients with a high atherosclerotic burden and claudication. It is unclear if goal-directed therapy of to achieve a decrease in cholesterol (
Molecular actions of PPARα in lipid metabolism and inflammation. Endocr Rev. 2018 Jul 17;: Authors: Bougarne N, Weyers B, Desmet SJ, Deckers J, Ray DW, Staels B, De Bosscher K Abstract Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor of clinical interest as a drug target in various metabolic disorders. PPARα also exhibits marked anti-inflammatory capacities. The first generation PPARα agonists, the fibrates, have however been hampered by drug-drug interaction issues, statin drop-in and ill-designed cardiovascular intervention trials. Notwithstanding...
Publication date: Available online 19 July 2018Source: Canadian Journal of CardiologyAuthor(s): G. B. John Mancini, Alice Y. Cheng, Kim Connelly, David Fitchett, Ronald Goldenberg, Shaun Goodman, Lawrence A. Leiter, Eva Lonn, Breay Paty, Paul Poirier, James Stone, David Thompson, Subodh Verma, Vincent Woo, Jean-Francois YaleAbstractA sea-change in the management of diabetes is occurring with the publication of clinical trials showing unequivocal cardiovascular (CV) protection through the use of certain antihyperglycemic agents. This change is similar to the change that occurred when lipid lowering with statins was first sh...
Unfortunately the name of one of the authors was spelled incorrectly in the published original article. The correct name is Alejandro Santos-Lozano. The original article got updated.
Statins prevent saphenous vein graft (SVG) disease and improve outcomes after coronary artery bypass graft surgery (CABG). However, the optimal postoperative statin dose remains unclear. The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events (ACTIVE) trial was undertaken to evaluate whether early postoperative high-dose statin therapy reduces SVG occlusion compared to conventional moderate-dose therapy.